AGMB Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 3.16%, SMA50 3.16%, SMA200 3.16%). The stock remains hovering near 52-week lows, trading -3.84% below its high and over 26.46% above its low. Average 10-day trading volume of 101.19 thousand shares is below the 3-month average of 146.30 thousand, indicating normal recent market interest.

AgomAb Therapeutics N.V. American Depositary Shares has 48.74 million shares outstanding. The public float is 11.24 thousand shares, elevated short interest at 0.24% of float. This equals 118.03 thousand shares. The short ratio is 0.19 days.

Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $36.00 to $28.00. The high target offers 126.42% upside. The low target suggests 76.1% downside. The mean target is $32.00. This offers 101.26% upside.

AgomAb Therapeutics N.V. American Depositary Shares (NASDAQ:AGMB) closed at $15.90 USD, losing -$0.31 (-1.91%) from the previous close of $16.21. The stock is currently mid-range between its 52-week high and low $12.66 and $17.45. With a market capitalization of about $397.50 thousand, AgomAb Therapeutics N.V. American Depositary Shares is classified as a micro-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 326.88 thousand shares, volume is running light vs its 52-week average. Headquartered in Antwerp, None, AgomAb Therapeutics N.V. American Depositary Shares operates in the Healthcare sector and the Biotechnology industry. Led by CEO Tim Knotnerus, the company employs approximately 57 people and listed since May 29, 2024. AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

currently trading near 52-week highs band. Valuation shows AgomAb Therapeutics N.V. American Depositary Shares trading at a premium to the broader market with a P/E of -10.84. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $32.00, suggesting 101.26% upside. Our AI forecast model points to short-term strength (9.75% over two weeks), a medium-term rise (31.95% over three months), and a longer-term gain (1138.18% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that AgomAb Therapeutics N.V. American Depositary Shares stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.75%, with price expected at $17.45 by March 17, 2026, within a range of $16.82 to $18.03 3-Month Outlook: Projected rise of 31.95%, reaching $20.98 by May 28, 2026, with a range of $10.42 to $29.91. 1-Year Outlook: Projected gain of 1138.18%, with price at $196.87 by March 03, 2027, within a range of $196.82 to $196.95.

AgomAb Therapeutics N.V. American Depositary Shares trades at a P/E ratio of -10.84, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 The P/FCF stands at 0.0, also above market averages.